Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Drugs and Drug Abuse Category						82.09M	60.71M	33.33M
Drugs and Drug Abuse Category Growth						35.23%	82.12%	-
Infectious Disease Detection						64.29M	42.03M	20.93M
Infectious Disease Detection Growth						52.96%	100.81%	-
Women's Health Testing						15.58M	10.12M	7.32M
Women's Health Testing Growth						53.87%	38.23%	-
Cardiac Marker Detection						4.74M	5.08M	3.59M
Cardiac Marker Detection Growth						-6.67%	41.56%	-
Tumor Detection Class						6.33M	3.53M	2.23M
Tumor Detection Class Growth						79.33%	58.64%	-
Other Testing						11.15M	8.25M	8.30M
Other Testing Growth						35.26%	-0.61%	-
Total						184.19M	129.72M	75.70M
Total Growth						41.99%	71.36%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	63.01M	-						1.49M	1.88M	3.10M
China Growth	-	-						-20.90%	-39.38%	-
Overseas	836.44M	-						182.70M	127.84M	-
Overseas Growth	-	-						42.91%	-	-
Europe	-	-						-	-	36.01M
Asia	-	-						-	-	22.63M
Americas	-	-						-	-	6.19M
Africa	-	-						-	-	7.29M
Oceania	-	-						-	-	485.10K
Total	899.45M	-						184.19M	129.72M	75.70M
Total Growth	-	-						41.99%	71.36%	-

Source: S&P Global Market Intelligence.